Apple’s (AAPL) next major AI move could potentially come from an unlikely source: Google. According to Bloomberg, the iPhone maker is closing in on
Latest News
Is This Texas-Based Company a No-Brainer Buy for Energy Investors?
Thomas Niel, The Motley Fool November 6, 2025 at 5:29 AM Key Points ExxonMobil is the largest integrated oil and gas company in the
Dominion Energy Stock Outlook: Is Wall Street Bullish or Bearish?
Dominion Energy, Inc. (D), based in Richmond, Virginia, operates a wide-ranging energy business that provides power and natural gas services to millions across multiple states.
The worst October layoffs data in 22 years is spearheading more losses in stocks
US stocks dropped sharply on Thursday as investors took in the worst layoff data for the month of October in over two decades. Employers
Cathie Wood's New Bitcoin Target: 'Only' $1.2 Million By 2030—And Stablecoins Are To 'Blame'
Ark Invest has adjusted its long-term bullish outlook on Bitcoin (CRYPTO: BTC) from $1.5 million by 2030 down to $1.2 million, citing the rapid
Robinhood keeps Bitcoin treasury option on the table
Robinhood Markets (Nasdaq: HOOD) is actively looking at the Bitcoin (BTC) treasury plan, a company executive said during the earnings call on Nov. 5.
3 Interest Rate Sensitive Stocks to Buy Before Rates Fall Off a Cliff
Investors looking to put capital to work in this difficult-to-predict market certainly have plenty to consider right now. Whether we’re talking about monetary policy
Trump Team Now Claims Its Trillions in Tariff Revenue Are ‘Incidental’
In arguments before the Supreme Court, the White House backed away from its claims that President Trump’s tariffs were about raising revenue.
Fox Crowned Melania Trump ‘Patriot Of The Year’ And You Know What Happened Next
An award created by Fox Nation, the streaming arm of Fox News, is staying in the family. It’s passing directly from Donald Trump to
Trump unveils deal to reduce prices for some obesity drugs. Follow live updates.
The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity in recent years.